我武生物(300357.SZ):公司已上市點刺產品包括“粉塵蟎皮膚點刺診斷試劑盒”等
格隆匯6月20日丨我武生物(300357.SZ)近期在接待機構調研時表示,在體內診斷產品方面,公司已上市點刺產品包括“粉塵蟎皮膚點刺診斷試劑盒”、“屋塵蟎皮膚點刺診斷試劑盒”、“黃花蒿花粉變應原皮膚點刺液”、“白樺花粉變應原皮膚點刺液”、“葎草花粉變應原皮膚點刺液”;另有5個點刺品種(包括懸鈴木花粉點刺液、德國小蠊點刺液、貓毛皮屑點刺液、狗毛皮屑點刺液、豚草花粉點刺液)處於III期臨牀試驗階段;“煙麴黴點刺液”獲得臨牀試驗批准;“皮炎診斷貼劑01貼”處於I期臨牀試驗階段。公司將根據產品規劃及市場需求,進一步豐富過敏診斷產品管線,力爭形成系列化的過敏診斷產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.